Q2041 is a valid 2023 HCPCS Code that could be used to indicate Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose for reimbursement purposes.
Q2041 belongs to Medical Care Type of Service and has been in effect since Jan 01, 2019.
Axicabtagene ciloleucel car+
Q2041 code information
| HCPCS code: | Q2041 |
| Description: | AXICABTAGENE CILOLEUCEL, UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE |
| Effective Date: | Jan 01, 2019 |
| Added Date: | Apr 01, 2018 |
| Termination Date: | HCPCS Q2041 was terminated on Nov 30, -0001 |
| Pricing indicator: | 51 - DRUGS |
| Multi Pricing indicator: | A - NOT APPLICABLE AS HCPCS PRICED UNDER ONE METHODOLOGY |
| Coverage code: | C - CARRIER JUDGMENT |
| BETOS code: | O1E - OTHER DRUGS |
| Action code: | N - NO MAINTENANCE FOR THIS CODE |
| Type of Service: |
1 - MEDICAL CARE
|
| Anesthesia BUQ: | 0 |
Below a selection of HCPCS codes related to Q2041